A phase II study of concurrent weekly carboplatin and paclitaxel combined with definitive radiotherapy for advanced-stage cervical cancer.

A phase II study of concurrent weekly carboplatin and paclitaxel combined with definitive radiotherapy for advanced-stage cervical cancer. - A phase II study of concurrent weekly carboplatin and paclitaxel combined with definitive radiotherapy for advanced-stage cervical cancer.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017232

Enrollment

Registered

2015-04-22

Start date

2012-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uterine cervical cancer

Interventions

Concurrent weekly carboplatin and paclitaxel combined with pelvic radiotherapy

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: FIGO stage IIIb or IVa cervical cancer

Exclusion criteria

Exclusion criteria: FIGO stage Ia-IIIa cervical cancer

Design outcomes

Primary

Measure	Time frame
Progression free survival	—

Countries

Japan

Contacts

Public ContactSeiji Mabuchi

Osaka University Hospital Obstetrics and Gynecology

smabuchi@gyne.med.osaka-u.ac.jp06-6879-3351

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026